Stay updated with breaking news from Liora Schultz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Higher doses of tisagenlecleucel improved survival outcomes in pediatric patients with B-ALL without increasing toxicity.
_on_a_T-cell_is_binding_to_a_molecule_on_a_cancer_-_Alpha_Tauri_3D_Graphics_M1_dc8762afeaee4937ad644739f274c7a5-620x480.jpg)
Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.